The key point I've been trying to make is that there is a very strong correlation between DES and MTF transsexualism, both here and in every other place I've looked too. Not only that, but among the "DES babes" I've chatted to or friended on facebook, probably close on half were born with genital abnormalities of some kind (often quite serious things like strangulated hernias or an obstructed urethra, that required surgery immediately after birth). Probably half or more have female body markers and signs of hormonal problems too. I have mainly been meeting these people on trans support sites so there is likely to be an element of selection bias there, but even so, it's pretty obvious that there was a massive problem with that drug, and that there's been a cover up of some kind. If it's happened in the past with one of these drugs, then who's to say it isn't still going on with others?
The way I see it, there's definitely been a cover up of some kind. If you look at the CDC website on DES sons:
http://www.cdc.gov/des/consumers/about/effects_sons.htmlthere's a whole bunch of claims on there that don't stack up.
It says "DES sons are not at increased risk for infertility". This claim is based on a study, Wilcox 1995. However if you look at what they did in that study, they didn't do anything to actually measure fertility. All they did was ask the participants questions about the number of children, their age when the first child was born etc. Men produce so many sperm cells that, even with a lowered sperm count, they'll still be able to get a woman pregnant. All you're really measuring by counting the number of children is how keen someone was to have children. In my own case, I eventually experienced problems with sexual function and ejaculate volume, but it didn't happen until I was in my 40s. I fathered both my children when I was in my early 30s, so even though my testicular function eventually went pear shaped, it didn't have any effect on the number of children I had. Probably the same is true for most other people in a similar situation too.
I've found 3 studies in which they did measure fertility in DES sons, and found plenty of problems:
http://www.ncbi.nlm.nih.gov/pubmed/772199J Reprod Med. 1976 Apr;16(4):147-53. "Structural and functional abnormalities in the sex organs of male offspring of mothers treated with diethylstilbestrol (DES)."
http://www.ncbi.nlm.nih.gov/pubmed/850321J Urol. 1977 Apr;117(4):477-80. "Pathological semen and anatomical abnormalities of the genital tract in human male subjects exposed to diethylstilbestrol in utero."
http://www.ncbi.nlm.nih.gov/pubmed/37351J Urol. 1979 Jul;122(1):36-9. "Association of diethylstilbestrol exposure in utero with cryptorchidism, testicular hypoplasia and semen abnormalities."
In those studies, nearly a third of their DES sons had severely abnormal semen, and there were similarly high rates of genital abnormalities too. So I think the CDC is fronting a massive whitewash there.
Another thing I've discovered is that the single largest cohort, or study group, of DES sons, the Mayo group, aren't typical DES sons at all. Their average exposure, 720mg over the course of the pregnancy, is around 15 times smaller than was the case for DES sons exposed to the standard "Smith and Smith" protocol for prevention of miscarriage (which is the vast majority of DES sons worldwide). Very few of the Mayo group had exposures starting earlier than 12 weeks after conception either, whereas in other studies, all the most severe genital abnormalities were associated with exposures starting earlier than 12 weeks. In other words, they've collected a bunch of people with a very small exposure to DES and who were exposed too late in the pregnancy to develop serious abnormalities from it, and made them their single largest study group of DES sons. Small wonder that they didn't find any clear evidence of abnormalities.
Here's one of the two studies they mention in which no clear evidence of genital abnormalities was found:
http://www.ncbi.nlm.nih.gov/pubmed/6357269It was a study of the effectiveness of DES in treating toxaemia of
late pregnancy, and it even says in the abstract:
"Those in the stilboestrol group started treatment at the 12th week of pregnancy on average..."which would explain why there wasn't clear evidence of genital abnormalities, since for the majority of the participants, exposure would have started too late in the pregnancy to cause genital abnormalities.
Under the "Smith and Smith" protocol, treatment was typically started at 7 weeks or as soon as the pregnancy was confirmed, hence this study doesn't really tell us anything about the incidence of genital abnormalities in typical DES sons.
In the other study in which no clear evidence of genital abnormalities was found, Leary 1984:
http://jama.jamanetwork.com/article.aspx?articleid=395455there isn't anything in the abstract to say when on average exposure started for the DES sons in the study, or what doses they were typically exposed to. However, since there's over 800 DES sons in the study, my guess is that it was drawing mainly from the Mayo cohort, in which case it's not surprising that there was no clear evidence of abnormalities.
There's another study mentioned on the CDC website,
http://www.cdc.gov/des/consumers/research/recent_psychosexual.html"Psychosexual Characteristics of Men and Women Exposed Prenatally to Diethylstilbestrol" (Titus-Ernstoff et al., 2003)
In that study, they appear to have focused entirely on sexual orientation, and scrupulously avoided asking any questions about gender identity. Whether that was accidental or deliberate I don't know, but it's certainly helped to conceal what is by far the most important consequence for most natal males of being exposed to DES!